How ADP-ribose affects the body's antiviral defenses
Determining mechanisms of innate immune modulation by ADP-ribosylation
['FUNDING_OTHER'] · UNIVERSITY OF KANSAS LAWRENCE · NIH-11095408
Researchers are exploring how a small chemical tag called ADP-ribose changes immune proteins to help people fight viral infections like coronavirus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KANSAS LAWRENCE (nih funded) |
| Locations | 1 site (LAWRENCE, UNITED STATES) |
| Trial ID | NIH-11095408 on ClinicalTrials.gov |
What this research studies
This project uses engineered coronaviruses that lack a viral protein called Mac1 to learn how ADP-ribosylation controls innate immune responses. The team will study how ADP-ribose tags are added and removed from key immune proteins using cell and virus models and molecular lab techniques. By comparing normal and Mac1-mutant viruses, researchers aim to see how these tags limit or enhance virus replication and immune signaling. Results could point to new ways to boost antiviral defenses or identify targets for antiviral drugs.
Who could benefit from this research
Good fit: People who have had recent or past coronavirus or other viral respiratory infections would be most relevant for related patient-sample or translational follow-up work.
Not a fit: Patients with conditions unrelated to viral infections or innate immune function are unlikely to benefit directly from this basic laboratory research.
Why it matters
Potential benefit: Findings could identify new targets or strategies to strengthen innate immunity or develop antivirals against coronaviruses and related viruses.
How similar studies have performed: Prior laboratory studies using Mac1-mutant coronaviruses have shown this viral macrodomain is important for replication and disease, so this approach builds on established findings.
Where this research is happening
LAWRENCE, UNITED STATES
- UNIVERSITY OF KANSAS LAWRENCE — LAWRENCE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FEHR, ANTHONY R — UNIVERSITY OF KANSAS LAWRENCE
- Study coordinator: FEHR, ANTHONY R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.